Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.04 USD | -3.82% | -14.34% | +64.78% |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 1,416 | 2,691 | - | - |
Enterprise Value (EV) 1 | 1,020 | 2,418 | 2,276 | 2,691 |
P/E ratio | -8.32 x | -17.1 x | -14.2 x | -11.4 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | - |
EV / Revenue | - | - | - | - |
EV / EBITDA | - | 39.6 x | 23.2 x | 22.8 x |
EV / FCF | -13.6 x | -18.7 x | -15.2 x | -16.3 x |
FCF Yield | -7.34% | -5.33% | -6.57% | -6.15% |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 50,674 | 58,456 | - | - |
Reference price 2 | 27.94 | 46.04 | 46.04 | 46.04 |
Announcement Date | 3/5/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | - | - | - |
EBITDA 1 | - | 61 | 98 | 118 |
EBIT 1 | -93 | -163.2 | -209.8 | -291.2 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | -83.98 | -154.2 | -210.2 | -282.8 |
Net income 1 | -83.98 | -150.4 | -200.6 | -282.8 |
Net margin | - | - | - | - |
EPS 2 | -3.360 | -2.700 | -3.240 | -4.050 |
Free Cash Flow 1 | -74.93 | -129 | -149.5 | -165.5 |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share 2 | - | - | - | - |
Announcement Date | 3/5/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | - | - | - | - | -38.15 | 12 | 18 | 25 | - | - |
EBIT 1 | - | -18.88 | -24.3 | -37.16 | -38.18 | -39.58 | -41.63 | -44.7 | -43.15 | -45.1 |
Operating Margin | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -18.88 | -20.84 | -31.74 | -32.09 | -36.07 | -39.98 | -45.95 | -45 | -48 |
Net income 1 | -12.52 | -18.88 | -20.84 | -31.74 | -32.09 | -35.19 | -38.61 | -43.76 | -39.65 | -41.5 |
Net margin | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -2.510 | -3.780 | -0.5100 | -0.3200 | -0.6400 | -0.6267 | -0.6733 | -0.7683 | -0.6650 | -0.6950 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 6/22/23 | 8/28/23 | 11/13/23 | 3/5/24 | 5/13/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | 395 | 273 | 415 | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | -74.9 | -129 | -150 | -166 |
ROE (net income / shareholders' equity) | - | -31.5% | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share 2 | - | -2.590 | -2.770 | - |
Capex 1 | 0.17 | 0.85 | 1.6 | 3 |
Capex / Sales | - | - | - | - |
Announcement Date | 3/5/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.78% | 2.69B | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+44.76% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- APGE Stock
- Financials Apogee Therapeutics, Inc.